Phase 3 Readout
TSHA: Phase 3 Topline: ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary
June 1, 2031. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2031
- Company
- Taysha Gene Therapies, Inc. (TSHA)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: ASPIRE Study: A Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary
- Indication
- Rett Syndrome